Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens

Journal of Thoracic and Cardiovascular Surgery

Volumn 140, Issue 2, 2010, Pages 352-355

  Mujoomdar, Aneil A ^a   Tilleman, Tamara R ^a   Richards, William G ^a   Bueno, Raphael ^a   Sugarbaker, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

EDR; extreme drug resistance; IDR; intermediate drug resistance; LDR; low drug resistance; malignant pleural mesothelioma; MPM; odds ratio; OR

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL TYPE; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIUM CELL; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIMARY MALIGNANT PLEURAL MESOTHELIOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEASIBILITY STUDIES; HUMANS; MESOTHELIOMA; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT SELECTION; PLEURAL NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 77955470538     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.11.072     Document Type: Article

References (21)

1. D.J. Sugarbaker, R.M. Flores, M.T. Jaklitsch, W.G. Richards, G.M. Strauss, and J.M. Corson et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1999 54 63 discussion 63-5
2. L.M. Krug, H.I. Pass, V.W. Rusch, H.L. Kindler, D.J. Sugarbaker, and K.E. Rosenzweiget al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma J Clin Oncol 27 2009 3007 3013
3. P. Ellis, A.M. Davies, W.K. Evans, A.E. Haynes, and N.S. Lloyd Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline J Thorac Oncol 1 2006 591 601 Review
4. S.R. Kalmadi, C. Rankin, M.J. Kraut, A.D. Jacobs, D.P. Petrylak, and D.J. Adelstein et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) Lung Cancer 60 2008 259 263
5. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
6. T.A. d'Amato, R.J. Landreneau, W. Ricketts, W. Huang, R. Parker, and E. Mechetner et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer J Thorac Cardiovasc Surg 133 2007 352 363
7. T.A. d'Amato, R.J. Landreneau, R.J. McKenna, R.S. Santos, and R.J. Parker Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer Ann Thorac Surg 81 2006 440 446 discussion 446-7
8. R.W. Holloway, R.S. Mehta, N.J. Finkler, K.T. Li, C.E. McLaren, and R.J. Parker et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol 87 2002 8 16
9. R.S. Mehta, R. Bornstein, I.R. Yu, R.J. Parker, C.E. McLaren, and K.P. Nguyen et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treat 66 2001 225 237
10. R.I. Haroun, R.E. Clatterbuck, M.C. Gibbons, P.C. Burger, R. Parker, and J.P. Fruehauf et al. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens J Neurooncol 58 2002 115 123
11. J.M. Lyons 3rd, J. Abergel, J.L. Thomson, C.T. Anthony, Y.Z. Wang, and L.B. Anthony et al. In vitro chemoresistance testing in well-differentiated carcinoid tumors Ann Surg Oncol 16 2009 649 655 Epub 2009 Jan 8
12. V. Loizzi, J.K. Chan, K. Osann, F. Cappuccini, P.J. DiSaia, and M.L. Berman Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy Am J Obstet Gynecol 189 2003 1301 1307
13. Exiquon diagnostics. http://www.exiqon.com/dxps/Documents/edr-4-pager. pdf-Last entered 2009 Oct 17.
14. J.P. van Meerbeeck, R. Gaafar, C. Manegold, R.J. Van Klaveren, E.A. Van Marck, and M. Vincent et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 2005 6881 6889
15. T. Schinköthe, S. Haeger, and M.R. Gabri Practical guidelines for diagnostic use of in vitro chemosensitivity tests Anticancer Res 27 2007 1365 1367
16. D. Schrag, H.S. Garewal, H.J. Burstein, D.J. Samson, D.D. Von Hoff, and M.R. Somerfield American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays J Clin Oncol 22 2004 3631 3638
17. P. Cortazar, A.F. Gazdar, E. Woods, E. Russell, S.M. Steinberg, and J. Williams et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing Clin Cancer Res 3 1997 741 747
18. D.H. Kern, and L.M. Weisenthal Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures J Nat Cancer Inst 82 1990 582 588
19. J.P. Fruehauf, and D.S. Alberts In vitro drug resistance versus chemosensitivity: two sides of different coins J Clin Oncol 23 2005 3641 3642
20. S. Chattopadhyay, R. Zhao, S.A. Krupenko, N. Krupenko, and I.D. Goldman The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line Mol Cancer Ther 5 2006 438 449
21. J.N. McAlpine, S.M. Eisenkop, and N.M. Spirtos Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays Gynecol Oncol 110 2008 360 364